Drug Profile
TAK 850
Alternative Names: TAK-850Latest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Takeda
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus infections; Influenza B virus infections; Influenza virus infections
Most Recent Events
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 24 Aug 2016 Takeda withdraws a phase II trial for Influenza virus infections (In adults, In volunteers, Prevention) in Japan (SC) (NCT02713061)
- 15 Mar 2016 Takeda plans a phase II trial for Influenza virus infections (In adults, In volunteers, Prevention) in Japan (SC) (NCT02713061)